Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals completes institutional component of $26.3 million entitlement offer

Along with the entitlement offer, Paradigm has raised $51.6 million via a placement to professional, institutional and sophisticated investors.
The new funds will be used to advance a pivotal phase 3 OA clinical trial

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has successfully completed the institutional component of its fully underwritten accelerated non-renounceable entitlement offer to raise about $9.8 million.

The retail component of the entitlement offer will open today and is expected to raise about $16.5 million, providing a total equity raising under the entitlement offer of about $26.3 million.

Retail entitlement offer

Eligible shareholders may participate in the retail entitlement offer at the same price ($1.50 per share) as the institutional offer at an offer ratio of 1 new share for every 8 shares held.

The retail entitlement offer closes at 5.00pm (AEST) on May 6, 2019.

READ: Paradigm Biopharmaceuticals raising $77.9 million to fund its pivotal phase 3 OA trial

Along with the entitlement offer, Paradigm has raised $51.6 million via a placement to professional, institutional and sophisticated investors across Australia, Asia and the US.

The new funds will allow Paradigm to advance its pivotal phase 3 OA clinical trial in the US, EU and Australia.

The funds will also be used to complete the phase 2/3 pivotal clinical trial in MPS.

READ: Paradigm Biopharmaceuticals phase 2b trial achieves key endpoints in OA of the knee

The company has already successfully achieved the endpoints of improved knee function and pain reduction for its phase 2b trial in OA of the knee.

The clinical trial subjects receiving Paradigm’s injectable pentosan polysulfate sodium (iPPS) were shown to have reduced bone marrow lesion (BML), indicating the possible regression of the disease.

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
consumer health segment overview
January 10 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use